

Recombinant Human Kallikrein 2/KLK2 Protein (His Tag)

Catalog No. PKSH032666

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Kallikrein-2;Glandular Kallikrein-1;hGK-1;Tissue Kallikrein-2;KLK2
Species	Human
Expression Host	HEK293 Cells
Sequence	Pro19-Pro261
Accession	P20151
Calculated Molecular Weight	27.9 kDa
Observed molecular weight	10-12&16-19&28-33 kDa
Tag	C-His
Bioactivity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 0.01 EU per µg of the protein as determined by the LAL method.
Storage	Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < -20°C.
Formulation	Supplied as a 0.2 µm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02% Tween 80, pH5.0.
Reconstitution	Not Applicable

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-I-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-I-Xaa or Leu-I-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen.

For Research Use Only

KLK2 is considered to be a biomarker for prostate cancer.